1102. Reconstitution of CMV-specific cell-mediated immunity during letermovir prophylaxis in hematopoietic stem cell recipients

BACKGROUND: Patients who are cytomegalovirus (CMV) seropositive (R+) prior to hematopoietic cell transplant (HCT), have 30% incidence of clinically significant CMV reactivation in the absence of prophylaxis. At our institution, letermovir prophylaxis through Day 100 is used in CMV R+ high-risk (HR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Abidi, Maheen, Gutman, Jonathan, Weinberg, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776896/
http://dx.doi.org/10.1093/ofid/ofaa439.1288

Ejemplares similares

Ejemplares similares